Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Makaleler > Tam Makale · 2019
Yazarlar: Münevver ERDİNÇ, Eugene R. Bleecker, J. Mark FitzGerald, Gary T. Ferguson, Peter Barker, Stephanie Sproule, Richard F. Olsson, Ubaldo J. Martin, Mitchell Goldman
LANCET RESPIRATORY MEDICINE, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2019, cilt 7, ss 46-59
DOI: 10.1016/s2213-2600(18)30406-5
Özet
Background Benralizumab is an interleukin-5 receptor a-directed cytolytic monoclonal antibody that has been shown to safely reduce exacerbations and improve lung function for patients with asthma. We assessed the long-term safety and efficacy of benralizumab for patients with severe, uncontrolled eosinophilic asthma.